Issue 6, 2012

Hypothesis: butyrate is not an HDAC inhibitor, but a product inhibitor of deacetylation

Abstract

The short-chain fatty acid butyrate is classically referred to as an inhibitor of histone deacetylases (HDACi), however evidence from direct assays is both sparse and contradictory. This paper assesses the strength of the historical evidence, potential gaps, inadequacies and simplifications in the butyrate-as-HDACi hypothesis. An alternate model to explain the action of butyrate is proposed wherein butyrate acts as a product inhibitor of deacetylation. The model makes testable predictions which may enable future determination of the mode of action of this and other SCFAs.

Graphical abstract: Hypothesis: butyrate is not an HDAC inhibitor, but a product inhibitor of deacetylation

Article information

Article type
Opinion
Submitted
24 Jan 2012
Accepted
23 Feb 2012
First published
28 Feb 2012

Mol. BioSyst., 2012,8, 1609-1612

Hypothesis: butyrate is not an HDAC inhibitor, but a product inhibitor of deacetylation

B. M. Corfe, Mol. BioSyst., 2012, 8, 1609 DOI: 10.1039/C2MB25028D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements